SavedAdd your journal

Journals / Üroonkoloji Bülteni / 2020 / Cilt: 19 - Sayı: 2

Current Approach in Radiation Therapy for Prostate Cancer

İlknur ALSAN ÇETİN
Pages
49–55
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The treatment decision should be based on personal preference after informing the patient about the advantages and disadvantages of each treatment approach.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prostate cancer is one of the most common malignancies in men.
📊
Key Findings & Data:Radiotherapy is one of the main treatment modalities in the treatment of prostate cancer.
💡
Conclusion & Impact:The treatment decision should be based on personal preference after informing the patient about the advantages and disadvantages of each treatment approach.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Prostate cancer is one of the most common malignancies in men. Radiotherapy is one of the main treatment modalities in the treatment of prostate cancer. The reflection of technological advances in the field of radiation oncology enables the safe application of higher doses of radiotherapy in the treatment of prostate cancer. In addition, improvements in normal tissue preservation are reflected in patients’ quality of life. Radiotherapy can be applied in all stages of prostate cancer and postoperative radiotherapy can be applied in appropriate indication. Side effects are expected to be observed more in patients undergoing postoperative radiotherapy. The treatment decision should be based on personal preference after informing the patient about the advantages and disadvantages of each treatment approach.

🔖

Cite This Article

ÇETİN, İ. A. (2020). Current Approach in Radiation Therapy for Prostate Cancer. Üroonkoloji Bülteni, Cilt: 19 - Sayı: 2, 49–55. https://ajindex.com/articles/334857

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bortfeld TR. IMRT: a review and preview. Phys Med Biol 2006;51:363-379
  2. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;16:969-974
  3. Merrick GS, Butler WM, Lief JH, Galbreath RW. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men 4. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of longterm outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327-333
  4. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850
  5. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostatespecific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31-40
  6. Song MK, Unruh ML, Manatunga A, et al. SPIRIT trial: A phase III pragmatic trial of an advance care planning intervention in ESRD. Contemp Clin Trials 2018;64:188-194
  7. Donovan JL, Hamdy FC, Lane JA, et al. ProtecT Study Group. PatientReported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2016;375:1425-1437
  8. Dearnaley D, Syndikus I, Mossop H, et al. CHHiP Investigators Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-1060
  9. Catton CN, Lukka H, Gu CS, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol 2017;35:1884-1890
  10. Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy FractionationSchedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 2016;34:2325-2332
  11. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localized prostate cancer (HYPRO): final efficacy results from a randomized, multicenter, open-label, phase 3 trial. Lancet Oncol 2016;17:1061-1069
  12. Shaikh T, Li T, Handorf EA, et al. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol P